Reading Time: 5 minutes
Medically Approved by Dr Aqua Asif (July 20 2025) and Mr Marc Laniado Consultant Urologist GMC: 3343931
Written by FTC Medical Team
At a Glance
The digital rectal exam (DRE) is no longer recommended for routine prostate cancer screening. In a landmark 2025 statement, the British Association of Urological Surgeons (BAUS) and Prostate Cancer UK declared the DRE a “poor test” that should be replaced by a simple PSA blood test followed by MRI if needed — a more accurate, objective, and patient-friendly pathway.
- No longer recommended — BAUS and Prostate Cancer UK confirm the DRE is unreliable for cancer screening
- Key limitation — the DRE only feels the back of the prostate, missing cancers in the front or middle of the gland
- Barrier to testing — 60% of men report anxiety about the DRE, and over a third avoid their GP because of it (Prostate Cancer UK)
- Modern pathway — a PSA blood test followed by MRI (if needed) is safer, more accurate, and guides targeted treatments like focal therapy
- What to do now — ask your GP for a PSA blood test; you do not need a DRE to begin a prostate cancer check
The digital rectal exam (DRE) is no longer recommended for routine prostate cancer screening. In June 2025, the British Association of Urological Surgeons (BAUS) and Prostate Cancer UK issued a landmark joint statement declaring the DRE a “poor test for prostate cancer” — a position now endorsed by the UK’s leading urological bodies.
This shift removes a significant barrier that has prevented many men from seeking help. According to Prostate Cancer UK, 60% of men expressed fear about the DRE, and over a third avoided speaking to their GP because of it. The modern diagnostic pathway — a simple PSA blood test followed by MRI if needed — is more accurate, objective, and aligned with current NICE guidelines (NG131).
What is a Digital Rectal Exam?
A digital rectal exam (DRE) is a physical examination where a clinician inserts a gloved, lubricated finger into the rectum to feel the back surface of the prostate gland. It was historically used alongside the PSA blood test to check for abnormalities such as hard lumps or unusual firmness.
Medical understanding has moved on significantly. The British Association of Urological Surgeons (BAUS) now describes the DRE as a “legacy of the historic pathway” that does not provide the reliable, objective information needed for accurate prostate cancer diagnosis. A 2018 systematic review in the Annals of Family Medicine (Naji et al.) confirmed the DRE’s poor sensitivity for detecting clinically significant prostate cancer.
Is the DRE still recommended for prostate cancer?
No. The digital rectal exam is no longer recommended as a routine prostate cancer screening test in the UK. In June 2025, BAUS and Prostate Cancer UK jointly declared the DRE a “poor test” that should be replaced by a PSA blood test as the first step, in line with NICE guideline NG131 for prostate cancer diagnosis and management.
What Are the Limitations of the DRE?
Limited coverage: A clinician’s finger can only feel the back (posterior) portion of the prostate. Cancers that develop in the front or middle of the gland — which many do — cannot be detected by touch alone. A “normal” DRE result can provide false reassurance whilst a significant cancer goes undetected.
Subjective assessment: The DRE relies entirely on a clinician’s sense of touch rather than objective measurement. Research published in the Journal of Clinical Urology (Sajjad et al., 2024) found that many men referred to a specialist with a supposedly abnormal DRE were found to have a normal prostate upon expert re-evaluation — causing unnecessary anxiety and further invasive tests.
| Feature | Digital Rectal Exam (DRE) | Modern Pathway (PSA + MRI) |
|---|---|---|
| Coverage | Posterior surface only | Entire prostate gland visualised |
| Objectivity | Subjective — clinician’s judgement | Objective — standardised PI-RADS scoring |
| Patient experience | Invasive; 60% of men report anxiety (PCUK) | Non-invasive PSA blood test first |
| Cancer detection | Misses anterior and central tumours | Detects tumours regardless of location |
| Treatment planning | Cannot guide targeted treatment | Enables focal therapy and targeted biopsy |
| UK endorsement | No longer recommended (BAUS/PCUK, 2025) | Recommended pathway (NICE NG131) |
Source: BAUS/Prostate Cancer UK joint statement (2025); NICE NG131
Why Does the DRE Deter Men from Getting Tested?
The DRE has been one of the biggest barriers preventing men from seeking a prostate cancer check. According to Prostate Cancer UK, 60% of men expressed concern about having a rectal exam, and of those, more than a third said they would avoid speaking to their GP about prostate concerns specifically because they feared the DRE.
This is particularly concerning for Black men, who are twice as likely to be diagnosed with prostate cancer and report greater cultural stigma around the examination. Removing the DRE from routine screening removes a barrier that has cost lives by delaying diagnosis.
What Has Replaced the DRE?
The modern prostate cancer diagnostic pathway recommended by NICE (NG131) relies on objective data rather than subjective touch. It begins with a simple PSA blood test. If the PSA level is raised, a multiparametric MRI (mpMRI) scan provides a detailed image of the entire prostate gland — far more information than a finger examination could ever deliver.
This approach has been shown to reduce unnecessary biopsies and detect clinically significant cancers that the DRE would miss, particularly those in the anterior and central zones of the prostate.
How Does Precision Diagnosis Enable Treatment?
The detailed imaging provided by MRI is the essential foundation for advanced, targeted treatments like focal therapy. By knowing exactly where the cancer is located, consultants at The Focal Therapy Clinic can use minimally invasive techniques such as HIFU (NICE-approved, IPG424) or NanoKnife IRE (NICE-approved, IPG768) to target cancerous tissue whilst preserving healthy structures.
In our clinic’s experience treating over 2,000 patients, focal therapy achieves 90%+ sexual function preservation and 97% urinary continence (FTC audit, n=265) — outcomes that are only possible because MRI-guided diagnosis tells us precisely where to treat.
“The move from DRE to MRI-guided diagnosis has transformed how we plan treatment. We can now offer men targeted focal therapy that treats the cancer whilst preserving their quality of life.”
Get Expert Advice & The Latest Research
Subscribe to our newsletter to receive the latest updates, expert insights, and breakthrough research on prostate cancer-delivered straight to your inbox.
What Should You Do Next?
You do not need a digital rectal exam to begin a prostate cancer check. The modern pathway starts with a simple PSA blood test, which your GP can arrange. If your PSA level is raised, the next step is an MRI scan — not a DRE.
If you have concerns about your prostate health, or if a PSA test or MRI has raised questions, The Focal Therapy Clinic offers specialist consultations with experienced consultant urological surgeons across seven UK locations. Our team can guide you through the modern diagnostic pathway and, if treatment is needed, discuss targeted options including focal therapy.
Key action: Ask your GP for a PSA blood test. You do not need to undergo a DRE for a prostate cancer check. If you are over 50 — or over 45 if you are Black or have a family history — speak to your GP about prostate screening.
FAQs
What is a digital rectal exam?
A digital rectal exam (DRE) is a physical examination where a clinician inserts a gloved, lubricated finger into the rectum to feel the back surface of the prostate gland. It was historically used alongside the PSA blood test to check for lumps or firmness that might suggest prostate cancer or other conditions.
Is a digital rectal exam essential for a prostate cancer check?
No. The British Association of Urological Surgeons (BAUS) and Prostate Cancer UK now agree that the DRE is a “poor test” for prostate cancer and is not a necessary part of a screening check. The recommended first step is a simple PSA blood test, followed by MRI if needed, in line with NICE guideline NG131.
Why is the DRE no longer recommended for screening?
The DRE is no longer recommended because it has major limitations. It can only feel the back of the prostate, meaning it misses cancers in the front or middle of the gland. It is also subjective (dependent on clinician judgement), and Prostate Cancer UK found that 60% of men were anxious about the exam — deterring them from seeking help. Modern MRI scans visualise the entire prostate and are far more accurate.
Is there any role for the DRE anymore?
The DRE is no longer recommended for routine cancer screening. However, a clinician may still use it to assess non-cancerous conditions such as benign prostatic hyperplasia (BPH), particularly if a man has urinary symptoms but a normal PSA level. It remains a clinical tool — it is simply no longer a cancer screening tool.
Can a digital rectal exam raise PSA?
Vigorous prostate massage (not part of a routine DRE) can cause a temporary PSA rise. However, clinicians are aware of this, and best practice is to draw blood for the PSA test before performing any physical examination of the prostate. A standard DRE should not significantly affect PSA results.
References
The British Association of Urological Surgeons & Prostate Cancer UK. (2025, June 9). Rectal Exam a “Poor Test for Prostate Cancer” — Surgeons and Charity Agree. BAUS. https://www.baus.org.uk/professionals/baus_business/news/289/rectal_exam_a_poor_test_for_prostate_cancer_surgeons_and_charity_agree/
Harding, T.A., et al. (2024). Optimising the use of the prostate-specific antigen blood test in asymptomatic men for early prostate cancer detection in primary care: report from a UK clinical consensus. The British Journal of General Practice, 74(745), e534-e543.
Kirby, M., et al. (2024). Is the digital rectal exam any good as a prostate cancer screening test? The British Journal of General Practice, 74(740), 137-139.
Sajjad, W., et al. (2024). Diagnostic value of the abnormal digital rectal examination in the modern MRI-based prostate cancer diagnostic pathway. Journal of Clinical Urology, 17(4), 412-418.
Naji, L., et al. (2018). Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. Annals of Family Medicine, 16(2), 149-154.
